Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Tereso J. Guzmán & Carmen M. Gurrola-Díaz. (2021) Glucokinase activation as antidiabetic therapy: effect of nutraceuticals and phytochemicals on glucokinase gene expression and enzymatic activity. Archives of Physiology and Biochemistry 127:2, pages 182-193.
Read now
Read now
Markus Boehm, Matthew Crawford, Jamie E. Moscovitz & Philip A. Carpino. (2018) Diabetes area patent participation analysis – part II: years 2011-2016. Expert Opinion on Therapeutic Patents 28:2, pages 111-122.
Read now
Read now
Articles from other publishers (29)
Wenjia Yang, Han Wu, Xiaoling Cai, Chu Lin, Ruoyang Jiao & Linong Ji. (2023) Evaluation of efficacy and safety of glucokinase activators—a systematic review and meta-analysis. Frontiers in Endocrinology 14.
Crossref
Crossref
Siddharth Yadav, Samuel Bharti & Puniti Mathur. (2023) GlucoKinaseDB: A comprehensive, curated resource of glucokinase modulators for clinical and molecular research. Computational Biology and Chemistry 103, pages 107818.
Crossref
Crossref
Ying Du, Leili Gao, Xinhua Xiao, Xin Hou & Linong Ji. (2022)
A multicentre, randomized, double‐blind, parallel, active‐ and placebo‐controlled Phase 3 clinical study of the glucokinase activator
PB
‐201 in treatment‐naive patients with type 2 diabetes mellitus: A study protocol
. Diabetes, Obesity and Metabolism 25:3, pages 649-655.
Crossref
Crossref
Ziyan Xie, Ting Xie, Jieying Liu, Qian Zhang & Xinhua Xiao. (2023) Glucokinase Inactivation Ameliorates Lipid Accumulation and Exerts Favorable Effects on Lipid Metabolism in Hepatocytes. International Journal of Molecular Sciences 24:5, pages 4315.
Crossref
Crossref
Tobias Kroon, Therese Hagstedt, Ida Alexandersson, Annett FermMarie PeterssonStefanie Maurer, Bader ZarroukiKristina Wallenius, Nicholas D. OakesJeremie Boucher. (2022) Chronotherapy with a glucokinase activator profoundly improves metabolism in obese Zucker rats. Science Translational Medicine 14:668.
Crossref
Crossref
Hilla Mills, Ronald Acquah, Nova Tang, Luke Cheung, Susanne Klenk, Ronald Glassen, Magali Pirson, Alain Albert, Duong Trinh Hoang & Thang Nguyen Van. (2022) Type 2 Diabetes Mellitus (T2DM) and Carbohydrate Metabolism in Relation to T2DM from Endocrinology, Neurophysiology, Molecular Biology, and Biochemistry Perspectives. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-11.
Crossref
Crossref
Ajmer Singh Grewal & Viney Lather. (2022) Small Molecule Allosteric Activators of Human Glucokinase for the
Treatment of Type 2 Diabetes: Current Status and Challenges. Current Drug Discovery Technologies 19:4.
Crossref
Crossref
Prateek Sharma, Sukhbir Singh, Neelam Sharma, Deepak Singla, Kumar Guarve & Ajmer Singh Grewal. (2022) Targeting human Glucokinase for the treatment of type 2 diabetes: an overview of allosteric Glucokinase activators. Journal of Diabetes & Metabolic Disorders 21:1, pages 1129-1137.
Crossref
Crossref
Ana Karen Estrada, Timoteo Delgado-Maldonado, Edgar E. Lara-Ramírez, Ana Verónica Martínez-Vázquez, Eyra Ortiz-Pérez, Alma D. Paz-González, Debasish Bandyopadhyay & Gildardo Rivera. (2022) Recent Advances in the Development of Type 2 Sodium-Glucose Cotransporter
Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Mini-Reviews in Medicinal Chemistry 22:4, pages 586-599.
Crossref
Crossref
Shinichiro Kawata, Akinobu Nakamura, Hideaki Miyoshi, Kelaier Yang, Ikumi Shigesawa, Yuki Yamauchi, Kazuhisa Tsuchida, Kazuno Omori, Kiyohiko Takahashi, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Yasuo Terauchi & Tatsuya Atsumi. (2021)
Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in
db/db
mice
. Diabetes, Obesity and Metabolism 24:3, pages 391-401.
Crossref
Crossref
Akinobu Nakamura. (2022) Glucokinase as a therapeutic target based on findings from the analysis of mouse models. Endocrine Journal 69:5, pages 479-485.
Crossref
Crossref
Akinobu Nakamura, Kazuno Omori & Yasuo Terauchi. (2021) Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?. Diabetes, Obesity and Metabolism 23:10, pages 2199-2206.
Crossref
Crossref
Saurabh C. Khadse, Nikhil D. Amnerkar, Krushna S. Dighole, Ashish M. Dhote, Vikas R. Patil, Deepak K. Lokwani, Vinod G. Ugale, Nitin B. Charbe & Vivekanand A. Chatpalliwar. (2020) Hetero-substituted sulfonamido-benzamide hybrids as glucokinase activators: Design, synthesis, molecular docking and in-silico ADME evaluation. Journal of Molecular Structure 1222, pages 128916.
Crossref
Crossref
Brian E. Ford, Shruti S. Chachra, Ahmed Alshawi, Alfie Brennan, Suzannah Harnor, Celine Cano, David J. Baker, David M. Smith, Rebecca J. Fairclough & Loranne Agius. (2020)
Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte
ATP
homeostasis during substrate challenge
. Diabetes, Obesity and Metabolism 22:11, pages 1985-1994.
Crossref
Crossref
Zhiwei Zeng, Shi-Ying Huang & Tao Sun. (2020) Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes. Diabetes Therapy 11:11, pages 2521-2538.
Crossref
Crossref
Ping Wu, Zhenyu Liu, Xiaohong Jiang & Hao Fang. (2020) An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes. Current Drug Targets 21:5, pages 445-457.
Crossref
Crossref
Konstantinos A. Toulis, Krishnarajah Nirantharakumar, Chrysa Pourzitaki, Anthony H. Barnett & Abd A. Tahrani. (2020) Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments. Drugs 80:5, pages 467-475.
Crossref
Crossref
Zachary Bloomgarden. (2019) Glucokinase and the potential of glucokinase activation in type 2 diabetes. Journal of Diabetes 11:8, pages 626-627.
Crossref
Crossref
Timilehin David Oluwajuyitan & Oluwole Steve Ijarotimi. (2019) Nutritional, antioxidant, glycaemic index and Antihyperglycaemic properties of improved traditional plantain-based (Musa AAB) dough meal enriched with tigernut (Cyperus esculentus) and defatted soybean (Glycine max) flour for diabetic patients. Heliyon 5:4, pages e01504.
Crossref
Crossref
Roberto de J. Sandoval-Muñíz, Belinda Vargas-Guerrero, Tereso J. Guzmán, Pedro M. García-López, Alma L. Martínez-Ayala, José A. Domínguez-Rosales & Carmen M. Gurrola-Díaz. (2018) Lupin gamma conglutin protein: effect on Slc2a2, Gck and Pdx-1 gene expression and GLUT2 levels in diabetic rats. Revista Brasileira de Farmacognosia 28:6, pages 716-723.
Crossref
Crossref
Yue Ma, Risheka Ratnasabapathy, Chioma Izzi-Engbeaya, Marie-Sophie Nguyen-Tu, Errol Richardson, Sufyan Hussain, Ivan De Backer, Christopher Holton, Mariana Norton, Gaelle Carrat, Blanche Schwappach, Guy A. Rutter, Waljit S. Dhillo & James Gardiner. (2018) Hypothalamic arcuate nucleus glucokinase regulates insulin secretion and glucose homeostasis. Diabetes, Obesity and Metabolism 20:9, pages 2246-2254.
Crossref
Crossref
Hiroki Fujieda, Masakazu Kogami, Masao Sakairi, Noriyasu Kato, Mitsuhiro Makino, Naoki Takahashi, Toshiyuki Miyazawa, Satoko Harada & Tokuyuki Yamashita. (2018) Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus. European Journal of Medicinal Chemistry 156, pages 269-294.
Crossref
Crossref
Brian Lu, Kiran Kurmi, Miguel Munoz-Gomez, Egon J. Jacobus Ambuludi, Jason M. Tonne, Kuntol Rakshit, Taro Hitosugi, Yogish C. Kudva, Aleksey V. Matveyenko & Yasuhiro Ikeda. (2018) Impaired β-cell glucokinase as an underlying mechanism in diet-induced diabetes. Disease Models & Mechanisms 11:6.
Crossref
Crossref
Zhengyu Wang, Xiaofan Shi, Huan Zhang, Liang Yu, Yanhua Cheng, Hefeng Zhang, Huibin Zhang, Jinpei Zhou, Jing Chen, Xu Shen & Wenhu Duan. (2017) Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry 139, pages 128-152.
Crossref
Crossref
Ziad H. Al-Oanzi, Sophia Fountana, Tabassum Moonira, Susan J. Tudhope, John L. Petrie, Ahmed Alshawi, Gillian Patman, Catherine Arden, Helen L. Reeves & Loranne Agius. (2017) Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes. Diabetes, Obesity and Metabolism 19:8, pages 1078-1087.
Crossref
Crossref
Mariela Glandt & Zachary Bloomgarden. 2017. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
999
1012
.
Mark F. McCarty. (2016) In type 1 diabetics, high-dose biotin may compensate for low hepatic insulin exposure, promoting a more normal expression of glycolytic and gluconeogenic enyzymes and thereby aiding glycemic control. Medical Hypotheses 95, pages 45-48.
Crossref
Crossref
Loranne Agius. (2015) Dietary carbohydrate and control of hepatic gene expression: mechanistic links from ATP and phosphate ester homeostasis to the carbohydrate-response element-binding protein. Proceedings of the Nutrition Society 75:1, pages 10-18.
Crossref
Crossref
Mariela Glandt & Zachary Bloomgarden. 2016. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
1
14
.